Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 and Hydroxychloroquine in High Risk MDS
NCT03929211Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in myelodysplastic syndrome (MDS), sponsored by Wake Forest University Health Sciences. Planned start May 2021; status: withdrawn.
02
Drugs
devimistat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03929211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929211.